menu
    • menu

    Company profile for Incyte Corporation

    NEW Drugs in Dev: 67
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Incyte's vision is to become a leading biopharmaceutical company by building a proprietary pipeline of novel small molecule drugs for serious unmet medical needs primarily in the area of oncology. The field of oncology is evolving rapidly and transforming how cancer is and will be treated. With a growing pipeline that includes innovative compounds in three major oncology areas -- onco-inflammation, immuno-oncology and targeted...
    Incyte's vision is to become a leading biopharmaceutical company by building a proprietary pipeline of novel small molecule drugs for serious unmet medical needs primarily in the area of oncology. The field of oncology is evolving rapidly and transforming how cancer is and will be treated. With a growing pipeline that includes innovative compounds in three major oncology areas -- onco-inflammation, immuno-oncology and targeted therapies -- we believe Incyte is at the center of this transformation in cancer care.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Incyte CorporationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1801 Augustine Cut-off Wilmington, DE 19803
    Telephone
    Telephone
    +1 1.855.446.2983
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.incyte.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Cosmoprof

    Cosmoprof

    Not Confirmed

    envelop Contact Supplier

    Cosmoprof

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Incyte To Report 2025 Q4 And Year-End Financial Results
    Incyte To Report 2025 Q4 And Year-End Financial Results

    27 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127068438/en/Incyte-to-Report-Fourth-Quarter-and-Year-End-2025-Financial-Results

    BUSINESSWIRE
    27 Jan 2026
    Share Share
    Incyte Japan Approves Zynyz For First-Line Advanced Anal Cancer
    Incyte Japan Approves Zynyz For First-Line Advanced Anal Cancer

    22 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251221187054/en/Incyte-Japan-Announces-Approval-of-Zynyz-retifanlimab-for-the-First-Line-Treatment-of-Advanced-Anal-Cancer

    BUSINESSWIRE
    22 Dec 2025
    Share Share
    Japan Approves Incyte's Minjuvi for R/R Follicular Lymphoma
    Japan Approves Incyte's Minjuvi for R/R Follicular Lymphoma

    22 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251221198206/en/Incyte-Japan-Announces-Approval-of-Minjuvi-tafasitamab-in-Combination-with-Rituximab-and-Lenalidomide-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-Lymphoma

    BUSINESSWIRE
    22 Dec 2025
    Share Share
    Incyte To Present At Upcoming Investor Conference
    Incyte To Present At Upcoming Investor Conference

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251218287907/en/Incyte-to-Present-at-Upcoming-Investor-Conference

    BUSINESSWIRE
    18 Dec 2025
    Share Share
    EU Approves Minjuvi for Relapsed/Refractory Follicular Lymphoma
    EU Approves Minjuvi for Relapsed/Refractory Follicular Lymphoma

    17 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251217282673/en/Incyte-Announces-European-Commission-Approval-of-Minjuvi-tafasitamab-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-Lymphoma

    BUSINESSWIRE
    17 Dec 2025
    Share Share
    Incyte Announces Change To Its Board Of Directors
    Incyte Announces Change To Its Board Of Directors

    12 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251212839561/en/Incyte-Announces-Change-to-its-Board-of-Directors

    BUSINESSWIRE
    12 Dec 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search